A 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the efficacy on blood glucose control and safety of five doses of LCQ908 (2, 5, 10, 15 and 20 mg) or sitagliptin 100 mg on a background therapy of metformin in obese patients with type 2 diabetes

Category Primary study
Registry of TrialsClinical Trials Peruvian Registry
Year 2009
This article has no abstract
Epistemonikos ID: 5754ff14981b168912d12ec8abe52674464d3c26
First added on: Apr 16, 2025